Abstract
Sixteen patients with locally advanced or metastatic head and neck cancer were treated with esorubicin (4t'-deoxydoxorubicin) at a dose of 30–35 mg/m2 i.v. every 3 weeks. One patient was lost to the follow up after one cycle, whereas in the 15 evaluable cases a total of 34 courses were administered (median per patient: 2, range: 1–6). Pretreatment for parameter lesions consisted of radiotherapy in 5, chemotherapy in 3 and both treatments in 1 patients respectively. Overall, one partial response, one stable disease and 13 progressions were documented. Severe (grade 3 and 4) leukopenia, thrombocytopenia and anemia were noted in 3, 1 and 1 patients respectively. The only patient developing leukopenia and thrombocytopenia of grade 4 subsequently died because of pneumonia. On the other hand, non-hematologic toxicity was generally mild. At this dose and schedule, esorubicin demonstrated an activity less than 20% in head and neck cancer and therefore, no further evaluation is warranted.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Arcamone F, Di Marco A, Casazza AM: Chemistry and pharmacology of new antitumor anthracyclines. In: Umerania M (ed) Advances in cancer chemotherapy. Japanese Science Society, Tokyo University Park Press, Baltimore, 1978, pp 297–312
Casazza AM: Experimental evaluation of anthracycline analogs. Cancer Treat Rep 63:835–844, 1973
Salmon SE, Young L, Soehulen B, Liu R: Antitumor activity of esorubicin in human tumor clonogenic assay with comparison to doxorubicin. J Clin Oncol 2:282–286, 1984
Giuliani FC, Kaplan NO: New doxorubicin analogs active against doxorubicin resistant colon tumor xenografts in the nude mouse. Cancer Res 40:4682–4687, 1980
Casazza AM, Savi G, Pratesi G and Di Marco A: Antitumor activity in mice of 4′-deoxydoxorubicin in comparison with doxorubicin. Eur J Cancer Clin Oncol 19:411–418, 1983
Villani F, Comazzi R, Genitoni V: Preliminary evaluation of myocardial toxicity of 4′-deoxydoxorubicin: Experimental and clinical results. Drugs Exptl Clin Res 3:223–231, 1985
Garewal HS, Robertone A, Salmon SE, Jones SE, Alberts DS, Brooks R: Phase I Trial of Esorubicin (4′-deoxydoxorubicin). J Clin Oncol 2:1034–1039, 1984
Bonfante V, Ferrari L, Brambilla C, Rossi A, Villani F, Bonadonna G: Phase I study with 4–deoxydoxorubicin. Invest New Drugs 2:287–295, 1984
Stanton GF, Raymond V, Wittes RE, Schulman P, Budman D, Boratz R, Williams L, Petroni GR, Geller NL, Honcock C, Kreis W, Young CW: Phase I and clinical pharmacological evaluation of 4′-deoxydoxorubicin in patients with advanced cancer. Cancer Res 45:1862–1868, 1985
Holdner EE, Ten Bokkel Huinink WW, Hansen HH, Bruntsch V, Van Globbeke M, Serm HJ, Ruedo HM, Rozencweig M: Phase II Trial of 4–deoxydoxorubicin in advanced gastro-intestial cancer. Proc Am Soc Clin Oncol 3:139, 1984
Wertheim MS, Kris MG, Gralla RJ, O'Connel JP, Fiore JJ, Kelsen DP, Burke MT, Cibos IR, Heelan RT, Young CW, Kalman LA: Phase II studies of three new anthracyclines in non-small cell lung cancer. Proc Am Soc Clin Oncol 4:190, 1985
Blum RH and Carter SK: Adriamycin: A new anti cancer drug with significant clinical activity. Ann Int Med 80:249–259, 1974
Miller AB, Hoogenstraten B, Staquet M, Winkler A: Reporting results of cancer treatment. Cancer 47:207–214, 1981
Gehan EA: The determination of the number of patients required in a preliminary and a follow-up trial of a new chemotherapeutic agent. J Chron Dis 13:346–353, 1961
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Frustaci, S., Gasparini, G., Veronesi, A. et al. Phase II study of esorubicin (4′ -deoxydoxorubicin) in locally advanced or metastatic head and neck carcinoma. Invest New Drugs 5, 307–309 (1987). https://doi.org/10.1007/BF00175303
Issue Date:
DOI: https://doi.org/10.1007/BF00175303